Highest-materiality recent filing
Mangoceuticals files lawsuit seeking >$73M against Clarity Ventures; CEO options repriced to $0.45
Filed lawsuit in Texas state court against Clarity Ventures seeking damages exceeding $73M for failure to deliver HIPAA-compliant ERP/eCommerce platform.
Mangoceuticals' MGX-0024 zero respiratory mortality in 29,000-bird trial; 60% H5N1 mortality cut
Three commercial field trials in India (~29,000 broilers) with MGX-0024 drinking water showed zero respiratory-related mortality vs. historical ~50%.
MangoRx's new $99/mo injectable TRT sees 336% MoM sales growth, 54% CAC drop
Month-over-month sales of injectable TRT program increased 336% since mid-December 2025 launch.
Mangoceuticals receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on Feb 4, 2026: bid price below $1.00 for 30 consecutive days.
Up to $100M Solana-focused digital asset treasury strategy launched via subsidiary Mango DAT, LLC.
Mangoceuticals raises $2.5M via registered direct offering and private placement
$2.5M gross proceeds from sale of 1.43M common shares at $1.295 and 500K pre-funded warrants at $1.29499.
Mangoceuticals borrows $75K at 18% from CEO-controlled trust; matures Dec 2026
On Dec 4, 2025, borrowed $75,000 from The Tiger Cub Trust, controlled by CEO Jacob D. Cohen.
Mangoceuticals clarifies GLP-1 programs: no direct contracts with Eli Lilly or Novo Nordisk
MangoRx Direct and PeachesRx Direct can prescribe branded GLP-1s (Zepbound, Wegovy) via third-party provider.
Mangoceuticals partners with Lilly and Novo Nordisk for GLP-1 access programs; $99/month membership
Launches MangoRx Direct and PeachesRx Direct providing access to Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) via telehealth.
Mangoceuticals leases Dallas office and separates from COO Hammer with severance
Enters 5-year lease for 2,467 sq ft Suite 245 at 17130 Dallas Parkway; base rent $4,852/mo + operating expenses.
Mangoceuticals grants 500k shares and 2M options to CEO; CFO and directors each receive 100k shares
CEO Jacob Cohen receives 500,000 common shares as 2025 bonus and options to purchase 2,000,000 shares at $2.30.
Mangoceuticals raises $1.1M via private placement of 709,677 shares at $1.55/share
Sold 709,677 restricted common shares at $1.55 per share to five accredited investors.
Mangoceuticals terminates Diabetinol licensing deal; cancels 1M shares issued to Navy Wharf
Mutually rescinded March 2025 Master Distribution Agreement for Diabetinol, effective July 30, 2025.
Mangoceuticals amends CEO trust note to convertible with warrants; conversion price $1.785
Amended $100k promissory note from CEO's Tiger Cub Trust into convertible note; conversion price set at $1.785/share.
Mangoceuticals subsidiary designates 1M shares of 6% Series B Convertible Preferred
Series B Preferred has $10 stated value, 6% cumulative dividend payable quarterly.
Mangoceuticals President and Director Tony Isaac Resigns Effective June 30, 2025
Antonios 'Tony' Isaac resigned as President and Board member, effective June 30, 2025.
Mangoceuticals issues ~498K shares via warrant exercises, conversion, and ELOC draw
Cashless warrant exercises: Abri Advisors (93,731 shares) and Clover Crest (131,250 shares) on June 2.
Mangoceuticals raises $116K in unit offering, converts $500K note into convertible debt
Issued 70,454 units at $1.65 each for $116,249, each unit includes 1 share and half warrant to buy 1 share at $3.00.
Mangoceuticals rescinds IP purchase and consulting pacts, cancels 1.65M shares
On May 22, 2025, entered rescission agreements with ArcStone, Smokeless, and Strategem.
Mangoceuticals settles lawsuit with 62,500 shares, gets $100k loan from CEO trust at 18%
Entered settlement with 1800 Diagonal Lending, issuing 62,500 restricted shares to dismiss lawsuit with prejudice (May 5, 2025).
Acquired IP from Smokeless Technology Corp. for 1,600,000 restricted shares of MGRX common stock and 10% royalty on gross pouch product sales.
Mangoceuticals sells $100K Series B preferred, borrows $500K at 18% from Indigo Capital
Sold 100 shares of Series B Convertible Preferred at $100K; stated value $1,100/share, convertible at $1.50 into up to 73,333 common shares.
Mangoceuticals issues 335,000 fully-vested shares as 2025 discretionary bonus
CEO Jacob Cohen received 200,000 shares; President Antonios Isaac received 60,000 shares.
Mangoceuticals issues 590,000 common shares on conversions of preferred stock and debt
March 28: 350 Series B Convertible Preferred shares (stated value $385,000) converted into 256,666 common shares at $1.50/share.
Mangoceuticals reports Series B Preferred conversions into 287,467 common shares
Three holders converted 392 Series B Preferred shares (aggregate stated value $431,200) at $1.50/share.
Series B Preferred holders convert ~609K shares of common stock, aggregate stated value $913K
On March 25, 2025: 116 shares (stated value $127,600) converted to 85,067 common shares.
Mangoceuticals secures exclusive US/Canada rights to Diabetinol®; 1M shares and royalty
Exclusive rights to Diabetinol® in US & Canada; nutraceutical for blood glucose/HbA1c management.
Stockholders approve Series B conversion price cut to $1.50 and 2022 equity plan expansion
Series B Preferred conversion price reduced to $1.50 (from $2.25); floor price removed; dividend rights eliminated.
Mangoceuticals enters advisory consulting agreement and receives $120K from warrant exercise
Issued 200,000 restricted shares to 6330 Investment & Consulting for 12-month strategic advisory services.
Engaged Vipragen Biosciences for efficacy studies on H5N1 prevention via drinking water solution.
Amends $20M patent deal to credit R&D costs; raises $710K via stock sales
Amends Patent Purchase Agreement; cash payments reduced to $306K from $373K as of Dec 31, 2024.
Mangoceuticals sells 70k shares at $1.50, expands COO role, grants subsidiary control
Sold 70,000 restricted shares to accredited investor for $105,000 at $1.50/share via exempt private placement.
Entered First Amendment with MAAB Global to convert $500,000 debt into up to 333,334 shares at $1.50/share.
Mangoceuticals converts $150K note into 100K shares; appoints Antonios Isaac as President & Director
Debt conversion with Mill End Capital: $150K promissory note converted to 100K restricted common shares at $1.50/share.
Mangoceuticals subsidiary creates Series A Preferred Stock granting CEO 51% voting control
Series A Preferred Stock of M&P subsidiary gives holders 51% of total vote on all shareholder matters.
Mangoceuticals raises $900k via Series B Preferred and warrants for 1.188M shares
Closed four SPAs from Dec 31, 2024 through Jan 6, 2025, selling 900 shares of Series B Preferred at $1,000 each for $900k total.
Mangoceuticals raises up to $1.25M via Series B Preferred and warrants
Issued 350 shares of Series B Preferred for $350K and warrants for 462K shares at $2.57-$2.71 exercise price.
Acquired mushroom patent WO 2023/086647 from Greenfield Investments for 515,000 restricted shares of common stock.
Service agreement with Greentree Financial Group for compliance filings, accounting advice, and tax return preparation; fee of $40,000 cash plus 40,000 restricted common shares.
Mangoceuticals enters CFO consulting agreement; $4k/month, 25k shares
Consulting agreement with CFO Eugene Johnston effective Oct 1, 2024 for 12 months.
Mangoceuticals regains Nasdaq minimum bid price compliance after reverse stock split
Received Nasdaq letter on Oct 30, 2024 confirming full compliance with Minimum Bid Price Requirement.
Sold 33,333 shares at $2.36 each for net proceeds of $78,787 under the $25M ELOC with Platinum Point Capital.
MangoRx Board initiates strategic alternatives review to maximize shareholder value
Formalized $150K promissory note with CEO's entity Cohen Enterprises at 8% interest, due Jan 2, 2025.
MangoRx faces Eli Lilly lawsuit over alleged copying of weight-loss drugs Zepbound/Mounjaro
Eli Lilly filed a lawsuit claiming MangoRx improperly copied its weight-loss medicines Zepbound and Mounjaro.
Mangoceuticals announces 1-for-15 reverse stock split to meet Nasdaq $1 bid price
Reverse stock split at 1:15 ratio effective October 16, 2024 at 12:01 a.m. ET.
MangoRx launches oral Tirzepatide weight loss tablet 'TRIM' at $399/month
TRIM is a compounded oral dissolvable Tirzepatide tablet priced at $399 per month.
Mangoceuticals issues shares and warrants to consultants, draws $521K from ELOC
Issued 150k shares to Veritas Consulting for $43,155 value; $7.5k/month cash for 3-month consulting.
MangoRx launches oral Semaglutide weight-loss treatment 'Slim' at $299/month
Launched oral Semaglutide ODT compounded with Vitamin B6, branded 'Slim', on MangoRx.com.
Mangoceuticals sells 250 Series B Preferred shares for $250,000 in fourth closing under SPA
Sold 250 Series B Preferred shares to institutional accredited investor for $250,000; effective price at 10% discount to $1,100 stated value.
Mangoceuticals sells 500 Series B Convertible Preferred shares for $500k; CEO car allowance raised
Sold 500 Series B Preferred shares at 10% discount to $1,100 stated value, raising $500k from institutional investor.
Pursuant to the Hammer Amendment, Ms. Hammer’s role with the Company was expanded to include serving as Chief Operating Officer of Mango & Peaches Corp.,
appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.
appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.
Max materiality 0.85 · Median 0.60 · Most common event other_material